At busy Visp site, Lonza will up microbial services by 50%
In an effort to up its development of microbial-derived proteins, Swiss CDMO Lonza will invest in its manufacturing capacities in its home country.
The extension will be good to go by the end of this year, the company said. The expanded development will strengthen the upstream, downstream and process analytics support for new projects. The microbial footprint at its Visp site will be consolidated, and new high-throughput equipment and automation processes will be added to increase efficiency and project delivery. That will include three liquid handling workstations, and the upgrades will help improve data generation.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.